Autoantibody:Autoantigen Competitor Decoys: Application to Cardiac Phenotypes.

Timothy Cardozo, Lila Cardozo, Mohamed Boutjdir

Frontiers in immunology 2022

filter terms:

Autoimmune diseases are often associated with autoantibodies that abnormally target self-antigens (autoantigens). An intuitive therapeutic strategy for diseases caused by aAbs is to design decoys, or soluble molecules that target the antigen combining site of these aAbs, thereby blocking binding of aAb to self-antigen and subsequent tissue damage. Here, we review the known decoy molecules of these types, discuss newer technological opportunities afforded by monoclonal antibody and structural biology advances, and discuss the challenges to this approach. Recent opportunities relevant to this approach for cardiac phenotypes, specifically Ro-associated long QT syndrome, are discussed. Copyright © 2022 Cardozo, Cardozo and Boutjdir.

Citation

Timothy Cardozo, Lila Cardozo, Mohamed Boutjdir. Autoantibody:Autoantigen Competitor Decoys: Application to Cardiac Phenotypes. Frontiers in immunology. 2022;13:812649